NAD bounces Notox to FTC
This article was originally published in The Tan Sheet
Executive Summary
Claims for A.D. Pharma's alcohol-intoxication reducer have been referred to the Federal Trade Commission after the firm failed to make a "bona fide good faith attempt to bring its advertising into compliance with NAD's recommendations," the Council of Better Business Bureaus division says in an Aug. 19 release. Notox was the subject of a NAD inquiry in the spring (1"The Tan Sheet" May 3, 2004, In Brief). At issue were claims that clinical studies indicate the Panax ginseng/citrus reticulate supplement "combats the effects of alcohol intoxication." The watchdog group notes that the television commercial NAD objected to has been permanently discontinued...
You may also be interested in...
Notox gets buzzed by NAD
Statements that "clinical test results show that Notox...combats the effects of alcohol intoxication" should be modified, the National Advertising Division tells A.D. Pharma following a recent review. Implied and explicit claims on TV, radio, and print ads and testimonials for the Panax ginseng/citrus reticulate supplement, found during routine monitoring, are not supported by a trial in 10 male subjects, the watchdog group adds. NAD also was troubled by claims that could lead consumers to believe that "Notox allows product users to drink and drive." A.D. Pharma said it modified the television spot prior to NAD's inquiry, and plans on revising its website...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.